

## Special Issue

# Biomedical Advances in ABC Transporters: From Bench to Bedside

### Message from the Guest Editor

The goal of this Special Issue, “Biomedical Advances in ABC Transporters: from Bench to Bedside”, is to present the state-of-the-art of our current knowledge about the roles and mechanisms of ABC transporters. Topics include but are not limited to:

- Bioinformatics and molecular evolution of ABC transporters;
- Structure-function relationship on ABC transporter-associated human diseases;
- ABC transporters v.s. multidrug resistance;
- Metabolism v.s. ABC transporters;
- Roles of ABC transporters in infectious diseases;
- Cell and animal models to study ABC transporters in human physiology and disease pathology;
- Drug discovery and drug design on the basis of structural and molecular findings;
- Targeted therapies to rescue defective ABC transporters;
- Targeted therapies to modulate ABC transporter functions;
- Perspectives related to genetic or functional defects of ABC transporters;
- Clinical trials and population-based studies in ABC transporter-associated disorders;
- Rare genetic diseases associated with ABC transporters.

---

### Guest Editor

Dr. Jyh-Yeuan Lee

Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

---

### Deadline for manuscript submissions

closed (31 December 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/131138](https://mdpi.com/si/131138)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).